22.79
+5.02%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Uniqure
From its filings with the US Securities and Exchange Commission
Uniqure is based in Amsterdam. Its shares trade on Nasdaq under the ticker QURE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $16.1m and a net loss of $199.0m. At that date it held total assets of $824.9m and shareholders' equity of $198.9m.
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington’s disease, refractory mesial temporal lobe epilepsy (“MTLE”), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (“SOD1-ALS”).
In September 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. We analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high-dose; n=12 low-dose) of which 12 patients per dose group had attained 36 months of follow-up and were evaluated at that time point. Outcomes for each dose group were compared to a propensity score-matched external control drawn from the Enroll-HD natural history data set (n=940 for high-dose; n=626 for low-dose).
A mean reduction from baseline in cerebrospinal neurofilament light protein (“CSF NfL”) of -8.2% was observed at 36 months in the high-dose of AMT-130 of the Phase I/II studies. CSF NfL is a well-characterized, supportive biomarker of neurodegeneration. Elevation in CSF NfL has been shown to be strongly associated with greater clinical severity of Huntington’s disease.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2014
- Employees
- 221
- Website
- uniqure.com ↗
- Head office
- PAASHEUVELWEG 25A, AMSTERDAM, 1105 BP
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. David MeekNon-Executive Independent Chairman of the Board$166,344
- Mr. Matthew KapustaChief Executive Officer, Executive Director, since 2015$3.1m
- Mr. Christian KlemtChief Financial Officer$1.3m
- Dr. Jeannette PottsChief Legal and Compliance Officer and Corporate Secretary$1.3m
- Dr. Walid Abi-SaabChief Medical Officer$1.5m
- Ms. Kylie OkeefeChief Customer and Strategy Officer
- Dr. Robert GutNon-Executive Director, since 2018$126,344
- Mr. Madhavan BalachandranNon-Executive Independent Director$133,844
- Ms. Rachelle JacquesNon-Executive Independent Director$128,844
- Mr. Jack KayeNon-Executive Independent Director$146,344
- Dr. Leonard PostNon-Executive Independent Director$133,844
- Dr. Jeremy SpringhornNon-Executive Independent Director$146,344
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 53
- Social
- 89
- Governance
- 21
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Uniqure NV has several strengths that contribute to its competitive advantage in the market:
Weaknesses
- Despite its strengths, Uniqure NV also faces certain weaknesses that could hinder its growth and success:
Opportunities
- Uniqure NV can leverage various opportunities to expand its market presence and generate growth:
Threats
- Uniqure NV faces certain threats that could impact its business operations and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.